Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23698866 | 0.82 | CHRM1 (0.40) | CHRM1PDE2APDE11A | |
| SCHEMBL20636616 | 0.79 | CHRM1 (0.35) | CHRM1 | |
| SCHEMBL12074157 | 0.77 | CHRM1 (0.39) | CHRM1PDE2APDE11A | |
| SCHEMBL23698954 | 0.77 | CHRM1 (0.39) | CHRM1 | |
| SCHEMBL23698878 | 0.77 | ALDH1A1 (0.34) | — | |
| SCHEMBL23712085 | 0.76 | CHRM1 (0.36) | CHRM1 | |
| SCHEMBL16937028 | 0.74 | CHRM1 (0.61) | CHRM1 | |
| SCHEMBL23698858 | 0.72 | CHRM1 (0.51) | CHRM1PDE2APDE11A | |
| SCHEMBL23698863 | 0.71 | CHRM1 (0.50) | CHRM1PDE2APDE11A | |
| SCHEMBL23698865 | 0.71 | CHRM1 (0.50) | CHRM1PDE2APDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162864-B2 | Condensed-cyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-10 | — | — | US | disclosed |
| EP-3858823-A1 | CONDENSED-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162864-B2 | Condensed-cyclic compound | SLC10A2, VIP, AVPR2 | CHRM1 576/4885PDE2A 76/4885PDE11A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.